Researchers use iPSCs to define optimal treatment for managing life-threatening arrhythmias

ECG results from a patient with LQTS (bottom), which have a prolonged QT interval, are shown relative to normal ECG results (top). Researchers used iPSCs derived from a young patient with LQTS to determine a course of treatment that helped manage the patient's life-threatening arrhythmias. Credit: Adler, E. 2013. J. Gen. Physiol. doi:10.1085/jgp.201310958 (image adapted from ECG tracings supplied by Robert Pass).

Researchers used induced pluripotent stem cells (iPSCs) derived from a young patient with Long QT syndrome (LQTS), a congenital heart disorder, to determine a course of treatment that helped manage the patient's life-threatening arrhythmias. The results, which appear in The Journal of General Physiology, could lead to improved treatments for LQTS and other channelopathies, diseases caused by disturbed ion channel function.

iPSCs— that have been genetically reprogrammed to function like —provide a valuable tool for studying diseases and developing customized drug therapies. Researchers from Columbia University Medical Center used iPSCs differentiated into cardiomyocytes (iPSCs-CMs) to study the physiological basis for arrhythmias in a four-year-old with LQTS.

The disease, which can cause arrhythmias that lead to seizures and sudden death, is caused by a mutation in any of various genes encoding cardiac ion channels or their associated proteins. In the case at hand, the child had mutation in the SCN5A gene, which encodes a sodium channel, and a common polymorphism in the KCNH2 gene, which encodes a potassium channel.

Using voltage clamp analyses of iPSCs-CMs derived from the affected child and his parents, the researchers determined that his arrhythmias were caused by the SCN5A mutation. They performed further in vitro testing using the iPSCs-CMs to identify the most appropriate regimen for correcting the aberrant activity associated with the defective ion channel.

The results show promise for using in vitro iPSC techniques in the development of individualized drug therapies for patients with LQTS and other channelopathies.

More information: Terrenoire, C., et al. 2013. J. Gen. Physiol. 141:61-72.

add to favorites email to friend print save as pdf

Related Stories

Induced pluripotent stem cells at risk for rejection

May 13, 2011

(PhysOrg.com) -- Biologists at UC San Diego have discovered that an important class of stem cells known as "induced pluripotent stem cells," or iPSCs, derived from an individual's own cells, could face immune ...

Recommended for you

Barriers preventing post-stroke care

6 hours ago

For stroke victims, rehabilitation is crucial to their recovery. But a Flinders University study conducted in Singapore found that rehabilitation rates following discharge from hospital are poor because of gaps in the continuum ...

Home-based rehabilitation for CVD patients

7 hours ago

Patients who are found to suffer from cardiovascular diseases often have long years of treatment ahead of them and are urged to drastically change their lifestyle. But what is probably the most difficult ...

New remote patient monitoring devices available

10 hours ago

(HealthDay)—Several new remote patient monitoring devices with useful applications are available or under development, according to an article published July 8 in Medical Economics.

Monitoring pulse after stroke may prevent a second stroke

21 hours ago

New research suggests that regularly monitoring your pulse after a stroke or the pulse of a loved one who has experienced a stroke may be a simple and effective first step in detecting irregular heartbeat, a major cause of ...

User comments